Revision Year: 2013 Publisher: Takeda Pharma A/S Denmark, Langebjerg 1, DK-4000, Roskilde, Denmark
XEFO 8 mg/2ml injection: powder and solvent for solution for injection.
Pharmaceutical Form |
---|
Powder and solvent for solution for injection. Powder: Yellow solid substance. Solvent: Clear, colourless liquid, practically free from particles. The osmolarity of the reconstituted solution is about 328 mosmol/kg and pH is about 8.7. |
One vial contains 8 mg lornoxicam.
After reconstitution in 2 ml solvent, reconstituted solution contains 4mg/ml of lornoxicam.
For a full list of excipients, see 6.1.
Active Ingredient | Description | |
---|---|---|
Lornoxicam |
Lornoxicam is a non-steroidal anti-inflammatory drug with analgesic properties and belongs to the class of oxicams. Lornoxicams mode of action is mainly related to the inhibition of the prostaglandin synthesis (inhibition of the cyclooxygenase enzyme) leading to desensitisation of peripheral nociceptors and consequently inhibition of inflammation. A central effect on nociception, which seems to be independent of anti-inflammatory effects has also been suggested. |
List of Excipients |
---|
Powder: Mannitol Solvent: Water for injection |
1 set contains:
Powder for injection: Amber glass vial with rubber stopper, sealed with aluminium snap-off closure.
Water for injection: 2 ml clear glass ampoule.
Pack Sizes: 1,5, 6 or 10 sets.
Not all pack sizes may be marketed.
Takeda Pharma A/S Denmark, Langebjerg 1, DK-4000, Roskilde, Denmark
Drug | Countries | |
---|---|---|
XEFO | Austria, Brazil, Estonia, Israel, Lithuania, Poland, Romania, Turkey, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.